Purdue Pharma and U.S. States Reach New Deal

Abstract

Article| May 2022 Purdue Pharma and U.S. States Reach New Deal Gordon Glanz Gordon Glanz Search for other works by this author on: This Site PubMed Google Scholar ASA Monitor May 2022, Vol. 86, 39. https://doi.org/10.1097/01.ASM.0000830868.37717.4a Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Cite Icon Cite Get Permissions Search Site Citation Gordon Glanz; Purdue Pharma and U.S. States Reach New Deal. ASA Monitor 2022; 86:39 doi: https://doi.org/10.1097/01.ASM.0000830868.37717.4a Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll PublicationsASA Monitor Search Advanced Search Topics: opioid epidemic, opioids, bankruptcy, community, oxycodone It's all over. Or is it? U.S. Bankruptcy Judge Robert Drain recently placed his stamp of approval on a settlement among members of the Sackler family who own Purdue Pharma LP and a handful of states that had been fighting its multibillion-dollar opioid deal. The new deal is “a remarkable and in general very positive development in this case,” Drain said in the bankruptcy court. Still, in the larger snapshot of the landscape, broader ramifications of accusations against Purdue Pharma and the opioid crisis remain. At least on the surface, the agreement marks a significant moment in the national opioid litigation, an effort by state, local, and tribal governments to hold companies across the vast pharmaceutical industry accountable for the crisis of opioid addiction that led to at least 500,000 deaths since 1999. While the Sacklers, heirs to the Purdue empire, have neither accepted personal responsibility nor issued a personal... You do not currently have access to this content.